Canbiola Appoints David Woycik, Jr. to its Corporate Advisory Board
May 06 2019 - 11:22AM
InvestorsHub NewsWire
Canbiola Appoints David Woycik,
Jr. to its Corporate Advisory Board and Completes a 300% Increased
Investment in its Duramed Division to Combat the Opioid
Crisis Adds
Pharmaceutical and Business Operations Expertise with Key
Relationships to Provide Growth Opportunities for
Canbiola
HICKSVILLE, NY -- May 6, 2019 -- InvestorsHub NewsWire --
Canbiola, Inc. (OTCQB: CANB) (“Canbiola” or the
“Company”), a developer, manufacturer and seller of a
variety of Cannabidiol (Hemp) based products such as oils, creams,
moisturizers, chews, isolate, gel caps, and concentrate, announced
today the appointment of Mr. David Woycik, Jr. to its Corporate
Advisory Board.
Canbiola Chief Executive Officer, Marco Alfonsi, commented,
“We are thrilled to have Mr. Woycik join our Corporate Advisory
Board. We look forward to his knowledge, advice and relationships
in the pharmaceutical field as we explore expanding our CBD product
portfolio and their awareness and distribution. In particular, Mr.
Woycik, Jr.’s experience, exposure and relationships with the Armed
Forces and Canine Companions for Independence and VetDogs of
America which are both ripe for opportunities with CBD and
Canbiola.”
Mr. David Woycik, Jr. stated, “I am extremely proud and honored
to become a member of Canbiola’s Corporate Advisory Board. As the
former Vice President and General Counsel of a major pharmaceutical
company, PharmaFair, Inc., I fully appreciate the need for
experienced and knowledgeable business men and women to assist this
new and exciting company for greater success in the future. As a
former pharmaceutical Executive, I was exposed to many FDA
regulatory and sales and marketing issues which will help in the
growth of Canbiola’s diverse product line and strategically assist
Canbiola as it advances its business.”
Canbiola increased its investment in Duramed by 300% to continue
the initial deployment of the sam®Pro 2.0 device to treat Chronic
Pain and decrease/eliminate the crisis level use of Opioid-based
Pain Medication for Workers Comp, Personal Injury, Wounded Warriors
and Veterans. The sam®Pro 2.0 rollout offered to patients via its
physician office program continues to ramp successfully and has
dozens of clinics prescribing the sam®Pro 2.0 to treat Chronic Pain
Patients to date.
About Canbiola,Inc.
Canbiola, Inc. (OTCQB: CANB) is a developer,
manufacturer and seller of a variety of Cannabidiol (Hemp) based
products such as oils, creams, moisturizers, chews, isolate, gel
caps, and concentrates. Canbiola has developed its own line of
proprietary products as well as seeking synergistic value through
acquisitions in the CBD and the medical cannabis industry. Cannabis
is currently federally illegal and has legalized for medical
purposes in some form in a limited number of states, but pure CBD
products are legal in all 50 states. Hemp CBD is the
non-psychoactive component (No THC) used for treatment of pain,
inflammation, and wellness programs. For more
information about Canbiola, Inc., please
visit: https://canbiola.com.
Additionally, Canbiola’s wholly owned subsidiary Pure Health
Products, based in Lacey, WA, is its prime development laboratory
and production facility. Canbiola’s Duramed division has
recently initiated deployment of the proprietary durable medical
device, sam®Pro 2.0, through its’ Physician network for the
treatment of Workers Comp Patients, Personal Injury Patients,
Wounded Warrior Care and Veterans via the application of the
only FDA cleared wearable-active Ultrasound developed treatment
device for in-home use to treat chronic pain and reduce or
eliminate the use of opioid-based pain medication while
accelerating the healing of musculoskeletal injuries.
Forward-Looking Statements
Forward-looking statements and risks and uncertainties discussed
in this letter contain forward-looking statements. The words
"anticipate," "believe," "estimate," "may," "intend," "expect," and
similar expressions identify such forward-looking statements.
Expected, actual results, performance, or achievements could differ
materially from those contemplated, expressed, or implied by the
forward-looking statements contained herein. Forward-looking
statements are subject to a number of risks and uncertainties,
including but not limited to, risks and uncertainties associated
with, among other things, the impact of economic, competitive, and
other factors affecting our operations, markets, products, and
performance. The matters discussed herein should not be construed
in any way, shape or manner of our future financial condition or
stock price.
Follow Canbiola on:
Twitter @CanbiolaHealth
Instagram @canbiola.inc or @canbiola_cbd or
@canbiola_medical_cbd
Investors and Media:
IR@canbiola.com
(516) 595-9544
CAN B (QB) (USOTC:CANB)
Historical Stock Chart
From Aug 2024 to Sep 2024
CAN B (QB) (USOTC:CANB)
Historical Stock Chart
From Sep 2023 to Sep 2024